Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Trial Details

NCT ID
NCT06293898
Phase
PHASE1
Sponsor
SystImmune Inc.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • BL-M07D1
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Diego, California, United States|32.71571,-117.16472
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Participants must meet all the following inclusion criteria to be eligible for participation in this study:
  • Signed the informed consent form voluntarily and agreed to follow the program requirements.
  • Either sex
  • Age: ≥18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →